Regenerative Medicine Market 2020 Global Trends Evaluation, Geographical Segmentation, and Investment Opportunities till 2026

The MarketWatch News Department was not involved in the creation of this content.

Nov 25, 2020 (AmericaNewsHour) —
The Regenerative Medicine Market report provides an in-depth analysis of the Healthcare & Pharmaceuticals during the forecast period 2017-2026 which consists of the industry overview including the market size, volume, growth rate and recent trends and developments in the market based on historical and current data. The report covers detailed information about the key players, market segments, growth drivers and restraints in the industry. The report delivers an insight into the Regenerative Medicine Market which allows our clients to make informed decisions regarding the growth of their businesses.

The Regenerative Medicine Market is anticipated to reach over USD 79.23 billion by 2026 according to a new research published by Polaris Market Research. In 2017, the cell therapy dominated the global Regenerative Medicine market, in terms of revenue. North America is expected to be the leading contributor to the global market revenue in 2017.
Regenerative medicine is a branch of medicine that regrows, and repairs the damaged cells in the human body. These medicines include the use of stem cells, tissue engineering, that further helps in developing new organ that function smoothly. These medicines have the caliber of developing an entire organ as these cells are multipotent. The cells are majorly isolated from bone marrow, and umbilical cord blood.

Download free Sample of This Strategic Report:- https://www.kennethresearch.com/sample-request-10070801

The regenerative medicine market is primarily driven by the increasing number of individuals suffering from cancer, rising need to monitor and treating these chronic diseases in the limited time. Furthermore, stringent government policies, proper reimbursement policies, and increasing government healthcare expenditure for developing healthcare infrastructure to also boost the market growth in coming years. Also, rising number of organ transplantation, and increasing number of products in pipeline that are waiting for approval create major opportunity for the regenerative medicines in the coming years. However, some of the ethical and religious concerns for the use of stem cells, and lack of proper regulatory for the approval of various drugs would impede the market growth during the forecast period.

North America generated the highest revenue in the Regenerative Medicine market in 2017, and is expected to be the leading region globally during the forecast period. Increasing number of patients suffering from chronic diseases, improved healthcare infrastructure and health facilities, accessibility of healthcare facilities, are the primary factors driving the market growth in this region. While, Asia Pacific to be the fastest growing region in the coming years. The growth in this region is majorly attributed to the developing healthcare infrastructure of the countries like India, & China, and rising awareness for the use of regenerative medicines as an effective treatment option for chronic diseases.

The key players operating in the Regenerative Medicine market include Organogenesis Inc., Vericel Corporation, Osiris Therapeutics, Inc., Stryker Corporation, and NuVasive, Inc., Medtronic Plc., Acelity, Cook Biotech Inc., Integra LifeSciences, and C.R. Bard. These companies launch new products and collaborate with other market leaders

Read more

Precision Medicine Group Secures Major Investment from Blackstone

NEW YORK & BETHESDA, Md.–(BUSINESS WIRE)–Nov 20, 2020–

Precision Medicine Group (PMG) and Blackstone (NYSE: BX) today announced that PMG, a leading next-generation provider of drug development and commercialization services, has completed a major investment and recapitalization led by funds managed by Blackstone (“Blackstone”). The investment includes significant participation from Precision’s co-founders, Ethan Leder and Mark Clein, as well as current shareholders Berkshire Partners, TPG Growth, Oak HC/FT, and Vida Ventures.

Bethesda, Maryland-based PMG is a leading provider of mission-critical services to help biopharmaceutical companies conduct clinical trials and bring novel therapies to market by integrating deep therapeutic knowledge, data and analytics, and human expertise. With precision medicine as its foundation, PMG’s specialized capabilities enable the development and delivery of more targeted treatments for patients, addressing the next wave of innovation in global health advancement, expanded access, and outcomes improvement.

This new round of investment will fuel the expansion of PMG’s global footprint and technical capabilities to help accelerate the development, approval, and commercial reach of breakthrough treatments from life science innovators. Blackstone’s deep understanding of the drug development process and extensive operating resources will help deliver significant value to the partnership.

Mark Clein, PMG CEO, said: “We are thrilled to have Blackstone join us for this next phase of growth. Their serious commitment to the life sciences and global scope and scale make them an ideal partner to support our vision of success and expanded capabilities for the next generation of bio-pharma innovators.”

Julia Kahr, a Senior Managing Director at Blackstone, said: “PMG has built a compelling set of services that address the most important challenges facing biopharmaceutical and diagnostic companies. We are eager to back Mark and Ethan and the highly talented employees around the world to support their deep and ongoing commitment to PMG’s clients and look forward to pursuing the immense opportunity ahead by leveraging new technologies, expertise, and scale. We are also delighted to be joining Berkshire, TPG Growth, Oak HC/FT, and Vida to help accelerate this success.”

Anushka Sunder, Managing Director at Blackstone, added: “We have high conviction in the unprecedented wave of innovation PMG’s clients are driving in personalized medicines and novel drug mechanisms, especially in oncology and rare disease. PMG integrates deep science, extensive biomarker and genetic data, evidence of economic value, and market access insights to improve the speed, cost, and success rates of bringing life-changing therapies to patients. We are excited to support the continued expansion of PMG’s platform and broad therapeutic reach.”

Goldman Sachs & Co. LLC acted as lead financial advisor to PMG. Jefferies LLC and Perella Weinberg Partners also acted as financial advisors to PMG and Debevoise & Plimpton LLP acted as legal advisor to PMG. Morgan Stanley & Co. LLC, BofA Securities, and Barclays acted as financial advisors and Sullivan & Cromwell LLP acted as legal advisor to Blackstone. Terms of the transaction were not disclosed.

About Precision Medicine Group:

Formed in 2012, Precision Medicine Group is a specialized services company supporting next generation approaches to

Read more

Medicine, Education, and Investment Jobs at High Risk of Losing Talent, According to Workforce Logiq’s New Q3 2020 Labor Market Report

Predictive workforce intelligence shows all but three U.S. states – New Hampshire, New Mexico, and New Jersey – decreased in employee volatility

Workforce Logiq, a global provider of AI-powered workforce intelligence, technology, and services, today released its Q3 2020 Workforce Management Benchmark Report. The market analysis, which offers a predictive quarterly snapshot of U.S. talent volatility for professional and knowledge workers, reveals the total number of these employees categorized as volatile – and more likely to switch jobs – is down 7% over last quarter.

“The COVID-19 pandemic continues to have a rollercoaster impact on the labor market. Our benchmarks indicate employment sentiment is stabilizing after a highly volatile second quarter,” said Jim Burke, Workforce Logiq’s CEO. “Given recent corporate downsizing announcements, new COVID-19 spikes, and continued economic difficulty, employee volatility and retention risk may pick back up through end-of-year. Every employer needs to be equipped with data and context to make fast, accurate, and cost-effective talent decisions that help them ride out the uncertainty and plan an optimal workforce to take their organizations into 2021.”

The report, which explores employment volatility across major industries, job functions, metropolitan statistical areas (MSAs), and states, is based on Workforce Logiq’s proprietary and patent-pending workforce analytics and data science. Key findings include:

  • All but three of the top 35 job categories – Doctors and Medicine (up 13%), Education (up 10%), and Investment (up 2%) – saw decreased risk of losing talent over the quarter. Public Safety (-33%) and Skilled Trade (-26%) showed the biggest volatility decreases. Of the 19 industry sectors, 13 showed quarterly score degradation compared to only five in the second quarter.

  • Arts, Entertainment, and Recreation jumped to the top spot for worker volatility. At 16% above the national average, this hard-hit industry moved ahead of Finance and Insurance (60.1), Mining, Quarrying, and Gas Extraction (60.0), Utilities (56.7), and Transportation and Warehousing (55.9) with the highest average TRR ScoreSM (60.3).

  • Recruiting jobs and finance roles are now tied for having the largest percentage of employees open to exploring new opportunities. Both functions are 76% above the national average for volatility. Marketing (74%), HR (66%), Investment (54%), and Engineering (52%) follow closely behind.

  • The utility industry experienced the highest increase in talent retention risk. The sector’s employment volatility increased 13% over Q2. Mining, Quarrying, and Gas Extraction was one of the few industries to show improvement (-9%).

  • District of Columbia (DC) is now the most volatile geographic area in the U.S., moving ahead of New York at 32% above the average for worker volatility. This shift is likely due to spikes in election and COVID-19 uncertainty, given DC’s heavy concentration of government and public service jobs and lack of operational control over federal buildings. All the top 25 MSAs, and all states except for New Hampshire, New Mexico, and New Jersey, decreased in volatility. Baltimore-Columbia-Townson, MD saw a considerable 27% improvement.

“Top workforce leaders anticipate and hedge against both retention risk and talent gaps with fast, strategic moves,” said Dr. Christy

Read more